Decongestant Market
完整報告名稱與涵蓋範圍
Decongestant Market Research Report by Product Type (Synthetic Decongestants, Aromatic Decongestants, Herbal Decongestants, Combination), by Formulation (Nasal, Oral, Topical), by Category (Prescription Based, Over the Counter), by Application (Nasal Allergies, Cold, Asthma, Rhinitis, Sinusitis, Nasal Polyps, Others), by Age Group (Pediatrics, Adults, Geriatrics), by Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035
報告摘要
Decongestant Market Research Report by Product Type (Synthetic Decongestants, Aromatic Decongestants, Herbal Decongestants, Combination), by Formulation (Nasal, Oral, Topical), by Category (Prescription Based, Over the Counter), by Application (Nasal Allergies, Cold, Asthma, Rhinitis, Sinusitis, Nasal Polyps, Others), by Age Group (Pediatrics, Adults, Geriatrics), by Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035
Market Overview
The global decongestant market is projected to grow from USD 28,965.35 million in 2024 to USD 57,810.82 million by 2035, registering a CAGR of 6.48% during 2025–2035. A decongestant is a medication designed to relieve nasal congestion caused by conditions such as colds, allergies, and sinus infections. It works by narrowing swollen blood vessels in the nasal passages, reducing inflammation, and improving airflow. Decongestants are commonly available in oral tablets, nasal sprays, and drops.
The global decongestant market is fueled by the increasing occurrence of respiratory diseases, which include colds, flu, sinusitis, and asthma. The process of urbanization and the poor quality of the air have played a major part in congestion-related illnesses that have escalated, especially in cities with a high population. Breathing contaminated air with pollutants like particulate matter, nitrogen dioxide, and ozone makes respiratory troubles worse. Besides, the seasonal allergies make the situation even worse, thus ensuring continuous demand for the quick-relief medications. As the World Health Organization (WHO) points out that respiratory illnesses are the main health burden, and the necessity for efficient decongestants keeps on rising all over the world.
Key Company Development
Sanofi has been very active in building up its decongestant product line by means of collaboration and innovation. The company is making improvements in the formulations and introducing new delivery systems that will encourage patient convenience and make the treatment more effective. Most of the attention has been directed towards the development of the products that can treat several symptoms at the same time, thereby ensuring the patient does not need to take many different drugs during cold and allergy seasons. At the same time, Sanofi is moving to tap the natural and herbal market as a result of the growing consumer demand for such solutions, whether for the pharmaceutical or the consumer health markets. Moreover, the company is partnering strategically with healthcare providers, pharmaceutical companies, and startup groups that work on alternative therapies.
Major Players
Key players in the global decongestant market are Pfizer, Johnson & Johnson, Sanofi, Cipla Ltd, AptarGroup, Inc., Perrigo Company PLC, PANADOL, and Procter & Gamble Company.
Report Attribute Details
Market Size 2024 USD 28,965.35 Million
Market Size 2035 USD 57,810.82 Million
CAGR (2025-2035) 6.48%
Base Year 2024
Market Forecast Period 2025-2035
Historical Data 2019-2024
Market Segmentations
By Product Type: Synthetic Decongestants – 6.35%, Aromatic Decongestants – 6.56%.
By Formulation: Nasal – 6.61%, Oral – 6.74%.
By Category: Prescription-Based – 6.04%, Over the Counter – 6.64%
By Application: Nasal Allergies – 6.75%, Cold – 6.72%.
By Age Group: Pediatrics – 6.96%, Adults – 6.64%
By Distribution Channel: Hospital Pharmacies – 6.02%, Drug Stores & Retail Pharmacies – 6.62%.
Regional Insights
The decongestant market is dominated by North America, which is a major healthcare spender with developed distribution channels and strong consumer awareness about cold and allergy treatments that have contributed to it. In 2024, with a value of USD 10,975.78 million, North America leads the global decongestant market, where high healthcare spending and OTC availability play a significant role in the market trend. The US is mounting regional success with the adoption of OTC products and R&D activities forming a strong base.
The European market is predominantly supported by a well-established pharmaceutical industry and favorable health regulations that promote the sale of OTC drugs. Countries such as Germany, France, and the United Kingdom demonstrate high usage of nasal sprays and oral preparations. Pharma has been valued at USD 8,641.87 million in Europe, facing fewer barriers to herbal and combination therapy due to the strong pharmaceutical infrastructure and the positive trend towards its use.
Population growth, increased disposable incomes, and rising urbanization are the main reasons for the Asia-Pacific market's rapid expansion. At USD 6,967.03 million, the Asia Pacific market shows powerful and fast development, supported by respiratory problems caused by pollution and the expanding availability of low-cost medical care. China and India are two major factors to consider due to the large numbers of patients and the increasing ease of getting to the doctor.
South America is gradually turning into a promising market, with Brazil and Argentina leading as a result of seasonal infections prevailing and healthcare infrastructure getting better. The adoption of OTC products is continuously increasing, contributing to the demand in urban centers. The development of e-commerce platforms is certainly making products more available in areas that are far away.
The decongestant market in the Middle East and Africa region is slowly growing due to the better healthcare infrastructure and the awareness of common respiratory diseases. The Gulf countries are utilizing modern distribution channels to satisfy the needs of consumers. Although there is a limit to the growth in Africa because of access issues, the market is showing steady progress because of the increasing availability of OTC products.
授權報價
| Single User Price | $4,950 USD |
| Multi User Licence (up to 10 users) | $5,950 USD |
| Enterprisewide Price (Global Site License) | $7,250 USD |
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 19
2 MARKET INTRODUCTION 23
2.1 DEFINITION 23
2.2 RESEARCH OBJECTIVE 23
2.3 MARKET STRUCTURE 24
3 RESEARCH METHODOLOGY 25
3.1 OVERVIEW 25
3.2 DATA FLOW 27
3.2.1 DATA MINING PROCESS 28
3.3 PURCHASED DATABASE: 29
3.4 SECONDARY SOURCES: 30
3.4.1 SECONDARY RESEARCH DATA FLOW: 31
3.5 PRIMARY RESEARCH: 32
3.5.1 PRIMARY RESEARCH DATA FLOW: 33
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 34
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE 34
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 35
3.6.1 CONSUMPTION & NET TRADE APPROACH 35
3.6.2 REVENUE ANALYSIS APPROACH 35
3.7 DATA FORECASTING 36
3.7.1 DATA FORECASTING TECHNIQUE 36
3.8 DATA MODELING 37
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 37
3.8.2 DATA MODELING: 37
3.9 TEAMS AND ANALYST CONTRIBUTION 39
4 MARKET DYNAMICS 41
4.1 INTRODUCTION 41
4.1.1 INNOVATION IN DRUG FORMULATIONS AND DELIVERY SYSTEMS 41
4.1.2 HEALTHCARE ACCESSIBILITY AND REGULATION 41
4.1.3 RISING DEMAND FOR NASAL SPRAYS AND INHALERS 42
4.2 DRIVERS 42
4.2.1 INCREASING INCIDENCE OF RESPIRATORY DISEASES 42
4.2.2 GROWING POPULARITY OF SELF-MEDICATION 42
4.3 RESTRAINTS 42
4.3.1 STRINGENT REGULATORY GUIDELINES 42
4.3.2 SIDE EFFECTS AND SAFETY CONCERNS ASSOCIATED WITH DECONGESTANTS 43
4.4 OPPORTUNITY 43
4.4.1 INCREASED DEMAND FOR NATURAL AND HERBAL DECONGESTANTS 43
4.4.2 DEVELOPMENT OF COMBINATION THERAPIES TARGETING MULTIPLE SYMPTOMS 43
4.5 IMPACT ANALYSIS OF COVID-19 44
4.5.1 IMPACT ON OVERALL HEALTHCARE 44
4.5.2 IMPACT ON GLOBAL DECONGESTANT MARKET 44
4.5.3 IMPACT ON SUPPLY CHAIN OF GLOBAL DECONGESTANT MARKET 44
4.5.4 IMPACT ON MARKET DEMAND OF GLOBAL DECONGESTANT MARKET 44
4.5.5 IMPACT ON PRICING OF GLOBAL DECONGESTANT MARKET 44
5 MARKET FACTOR ANALYSIS 46
5.1 SUPPLY/VALUE CHAIN ANALYSIS 46
5.1.1 RAW MATERIAL PROCUREMENT 46
5.1.2 MANUFACTURING 46
5.1.3 PACKAGING & LABELLING 46
5.1.4 DISTRIBUTION AND RETAIL 46
5.1.5 RETAIL & CONSUMER DEMAND 47
5.2 PORTER’S FIVE FORCES MODEL 48
5.2.1 THREAT OF NEW ENTRANTS 49
5.2.2 THREAT OF SUBSTITUTES 49
5.2.3 BARGAINING POWER OF SUPPLIERS 49
5.2.4 BARGAINING POWER OF BUYERS 50
5.2.5 INTENSITY OF RIVALRY 50
6 GLOBAL DECONGESTANT MARKET, BY PRODUCT TYPE 52
6.1 INTRODUCTION 52
6.1.1 SYNTHETIC DECONGESTANTS 52
6.1.2 AROMATIC DECONGESTANTS 52
6.1.3 HERBAL DECONGESTANTS 52
6.1.4 COMBINATION 52
7 GLOBAL DECONGESTANT MARKET, BY FORMULATION 54
7.1 INTRODUCTION 54
7.1.1 NASAL 54
7.1.1.1 NASAL SPRAY 54
7.1.1.2 NASAL DROPS 54
7.1.1.3 INHALERS 54
7.1.2 ORAL 54
7.1.2.1 TABLETS & CAPSULES 54
7.1.2.2 LIQUIDS & SYRUPS 54
7.1.3 TOPICAL 55
7.1.3.1 GELS 55
7.1.3.2 PATCHES 55
8 GLOBAL DECONGESTANT MARKET, BY CATEGORY 57
8.1 INTRODUCTION 57
8.1.1 PRESCRIPTION-BASED 57
8.1.2 OVER THE COUNTER 57
9 GLOBAL DECONGESTANT MARKET, BY APPLICATION 59
9.1 INTRODUCTION 59
9.1.1 NASAL ALLERGIES 59
9.1.2 COLD 59
9.1.3 ASTHMA 59
9.1.4 RHINITIS 59
9.1.5 SINUSITIS 59
9.1.6 NASAL POLYPS 59
9.1.7 OTHERS 60
10 GLOBAL DECONGESTANT MARKET, BY AGE GROUP 62
10.1 INTRODUCTION 62
10.1.1 PEDIATRICS 62
10.1.2 GERIATRICS 62
11 GLOBAL DECONGESTANT MARKET, BY DISTRIBUTION CHANNEL 64
11.1 INTRODUCTION 64
11.1.1 HOSPITAL PHARMACIES 64
11.1.2 DRUG STORES & RETAIL PHARMACIES 64
11.1.3 ONLINE PHARMACIES 64
12 GLOBAL DECONGESTANT MARKET, BY REGION 66
12.1 INTRODUCTION 66
12.1.1 NORTH AMERICA 67
12.1.1.1 US 69
12.1.1.2 CANADA 71
12.1.1.3 MEXICO 73
12.1.2 EUROPE 75
12.1.2.1 GERMANY 77
12.1.2.2 UK 79
12.1.2.3 FRANCE 81
12.1.2.4 ITALY 83
12.1.2.5 SPAIN 85
12.1.2.6 TURKEY 87
12.1.2.7 REST OF EUROPE 89
12.1.3 ASIA-PACIFIC 91
12.1.3.1 JAPAN 93
12.1.3.2 CHINA 95
12.1.3.3 INDIA 97
12.1.3.4 SOUTH KOREA 99
12.1.3.5 INDONESIA 101
12.1.3.6 MALAYSIA 103
12.1.3.7 AUSTRALIA 104
12.1.3.8 SINGAPORE 106
12.1.3.9 REST OF ASIA PACIFIC 108
12.1.4 SOUTH AMERICA 110
12.1.4.1 BRAZIL 112
12.1.4.2 ARGENTINA 114
12.1.4.3 REST OF SOUTH AMERICA 116
12.1.5 MIDDLE EAST & AFRICA 118
12.1.5.1 SOUTH AFRICA 120
12.1.5.2 GCC COUNTRIES 122
12.1.5.3 SAUDI ARABIA 124
12.1.5.4 REST OF MIDDLE EAST AND AFRICA 126
13 COMPETITIVE LANDSCAPE 128
13.1 INTRODUCTION 128
13.2 MARKET SHARE ANALYSIS, 2024 128
14 COMPANY PROFILES 129
14.1 PFIZER. 129
14.1.1 COMPANY OVERVIEW 129
14.1.2 PRODUCTS OFFERED 129
14.1.3 SWOT ANALYSIS 130
14.1.4 KEY STRATEGY 130
14.2 CIPLA LTD. 131
14.2.1 COMPANY OVERVIEW 131
14.2.2 PRODUCTS OFFERED 131
14.2.3 SWOT ANALYSIS 132
14.2.4 KEY STRATEGY 132
14.3 GLAXOSMITHKLINE (GSK)/ PANADOL 133
14.3.1 COMPANY OVERVIEW 133
14.3.2 PRODUCTS OFFERED 133
14.3.3 SWOT ANALYSIS 134
14.3.4 KEY STRATEGY 134
14.4 JOHNSON & JOHNSON 135
14.4.1 COMPANY OVERVIEW 135
14.4.2 PRODUCTS OFFERED 135
14.4.3 SWOT ANALYSIS 136
14.4.4 KEY STRATEGY 136
14.5 APTARGROUP, INC. 137
14.5.1 COMPANY OVERVIEW 137
14.5.2 PRODUCTS OFFERED 137
14.5.3 SWOT ANALYSIS 139
14.5.4 KEY STRATEGY 139
14.6 PROCTOR & GAMBLE COMPANY 140
14.6.1 COMPANY OVERVIEW 140
14.6.2 PRODUCTS OFFERED 140
14.6.3 SWOT ANALYSIS 141
14.6.4 KEY STRATEGY 141
14.7 RECKITT BENCKISER GROUP PLC 142
14.7.1 COMPANY OVERVIEW 142
14.7.2 PRODUCTS OFFERED 142
14.7.3 SWOT ANALYSIS 143
14.7.4 KEY STRATEGY 144
14.8 SANOFI 145
14.8.1 COMPANY OVERVIEW 145
14.8.2 PRODUCTS OFFERED 145
14.8.3 SWOT ANALYSIS 146
14.8.4 KEY STRATEGY 147
14.9 PERRIGO COMPANY PLC 148
14.9.1 COMPANY OVERVIEW 148
14.9.2 PRODUCTS OFFERED 148
14.9.3 SWOT ANALYSIS 149
14.9.4 KEY STRATEGY 149
14.10 DR. REDDY’S LABORATORIES 150
14.10.1 COMPANY OVERVIEW 150
14.10.2 PRODUCTS OFFERED 150
14.10.3 SWOT ANALYSIS 151
14.10.4 KEY STRATEGY 151
15 DATA CITATIONS 152
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 38
TABLE 2 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 53
TABLE 3 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 56
TABLE 4 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 58
TABLE 5 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 61
TABLE 6 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 63
TABLE 7 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 65
TABLE 8 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY REGION, 2019–2035 (USD MILLION) 67
TABLE 9 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 67
TABLE 10 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 67
TABLE 11 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 68
TABLE 12 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 68
TABLE 13 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 68
TABLE 14 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 69
TABLE 15 US DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 69
TABLE 16 US DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 69
TABLE 17 US DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 69
TABLE 18 US DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 70
TABLE 19 US DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 70
TABLE 20 US DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 70
TABLE 21 CANADA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 71
TABLE 22 CANADA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 71
TABLE 23 CANADA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 71
TABLE 24 CANADA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 72
TABLE 25 CANADA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 72
TABLE 26 CANADA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 72
TABLE 27 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 73
TABLE 28 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 73
TABLE 29 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 73
TABLE 30 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 74
TABLE 31 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 74
TABLE 32 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 74
TABLE 33 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 75
TABLE 34 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 75
TABLE 35 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 75
TABLE 36 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 76
TABLE 37 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 76
TABLE 38 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 76
TABLE 39 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 77
TABLE 40 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 77
TABLE 41 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 77
TABLE 42 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 77
TABLE 43 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 78
TABLE 44 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 78
TABLE 45 UK DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 79
TABLE 46 UK DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 79
TABLE 47 UK DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 79
TABLE 48 UK DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 80
TABLE 49 UK DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 80
TABLE 50 UK DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 80
TABLE 51 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 81
TABLE 52 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 81
TABLE 53 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 81
TABLE 54 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 82
TABLE 55 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION)
TABLE 56 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 82
TABLE 57 ITALY DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 83
TABLE 58 ITALY DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION
TABLE 59 ITALY DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION)
TABLE 60 ITALY DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 61 ITALY DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION)
TABLE 62 ITALY DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 84
TABLE 63 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 85
TABLE 64 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION)
TABLE 65 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION)
TABLE 66 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION
TABLE 67 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION)
TABLE 68 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 86
TABLE 69 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 87
TABLE 70 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 87
TABLE 71 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION)
TABLE 72 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 88
TABLE 73 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION)
TABLE 74 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 88
TABLE 75 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 89
TABLE 76 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 89
TABLE 77 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 89
TABLE 78 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 89
TABLE 79 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 90
TABLE 80 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 90
TABLE 81 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 91
TABLE 82 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 91
TABLE 83 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 91
TABLE 84 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 92
TABLE 85 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 92
TABLE 86 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 92
TABLE 87 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 93
TABLE 88 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 93
TABLE 89 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION)
TABLE 90 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 91 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION)
TABLE 92 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 94
TABLE 93 CHINA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 95
TABLE 94 CHINA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 95
TABLE 95 CHINA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION)
TABLE 96 CHINA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 97 CHINA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION)
TABLE 98 CHINA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 96
TABLE 99 INDIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 100 INDIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION)
TABLE 101 INDIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION)
TABLE 102 INDIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 103 INDIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION)
TABLE 104 INDIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 98
TABLE 105 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 99
TABLE 106 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 99
TABLE 107 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 99
TABLE 108 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 100
TABLE 109 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 100
TABLE 110 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 100
TABLE 111 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 101
TABLE 112 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 101
TABLE 113 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 101
TABLE 114 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 102
TABLE 115 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 102
TABLE 116 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 102
TABLE 117 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 103
TABLE 118 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 103
TABLE 119 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 103
TABLE 120 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 104
TABLE 121 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 104
TABLE 122 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 104
TABLE 123 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 104
TABLE 124 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 105
TABLE 125 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 105
TABLE 126 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 105
TABLE 127 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 105
TABLE 128 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 106
TABLE 129 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 106
TABLE 130 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 106
TABLE 131 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 106
TABLE 132 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 107
TABLE 133 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 107
TABLE 134 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 107
TABLE 135 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 108
TABLE 136 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 108
TABLE 137 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 108
TABLE 138 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 109
TABLE 139 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 109
TABLE 140 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 109
TABLE 141 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 110
TABLE 142 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 110
TABLE 143 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 110
TABLE 144 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 111
TABLE 145 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 111
TABLE 146 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 111
TABLE 147 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 112
TABLE 148 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 112
TABLE 149 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION)
TABLE 150 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 151 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION)
TABLE 152 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 113
TABLE 153 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 114
TABLE 154 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 114
TABLE 155 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 114
TABLE 156 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 115
TABLE 157 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 115
TABLE 158 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 115
TABLE 159 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 116
TABLE 160 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 116
TABLE 161 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 116
TABLE 162 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 117
TABLE 163 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 117
TABLE 164 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 117
TABLE 165 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 118
TABLE 166 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 118
TABLE 167 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 118
TABLE 168 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 119
TABLE 169 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 119
TABLE 170 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 119
TABLE 171 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 120
TABLE 172 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 120
TABLE 173 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 120
TABLE 174 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 121
TABLE 175 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 121
TABLE 176 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 121
TABLE 177 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 122
TABLE 178 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 122
TABLE 179 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 122
TABLE 180 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 123
TABLE 181 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 123
TABLE 182 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 123
TABLE 183 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 124
TABLE 184 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 124
TABLE 185 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 124
TABLE 186 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 125
TABLE 187 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 125
TABLE 188 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 125
TABLE 189 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 126
TABLE 190 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019–2035 (USD MILLION) 126
TABLE 191 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019–2035 (USD MILLION) 126
TABLE 192 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019–2035 (USD MILLION) 127
TABLE 193 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019–2035 (USD MILLION) 127
TABLE 194 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 127
TABLE 195 PFIZER. COMPANY: PRODUCTS OFFERED 129
TABLE 196 CIPLA LTD. PRODUCTS OFFERED 131
TABLE 197 GLAXOSMITHKLINE (GSK)/ PANADOL : PRODUCTS OFFERED 133
TABLE 198 JOHNSON & JOHNSON: PRODUCTS OFFERED 135
TABLE 199 APTARGROUP, INC. COMPANY: PRODUCTS OFFERED 137
TABLE 200 PROCTOR & GAMBLE COMPANY PRODUCTS OFFERED 140
TABLE 201 RECKITT BENCKISER GROUP PLC CHEMICAL LTD: PRODUCTS OFFERED 142
TABLE 202 SANOFI: PRODUCTS OFFERED 145
TABLE 203 PERRIGO COMPANY PLC: PRODUCTS OFFERED 148
TABLE 204 DR. REDDY’S LABORATORIES: PRODUCTS OFFERED 150
LIST OF FIGURES
FIGURE 1 GLOBAL DECONGESTANT MARKET (BY REGION), 2024 21
FIGURE 2 GLOBAL DECONGESTANT MARKET: STRUCTURE 24
FIGURE 3 PORTER'S FIVE FORCES ANALYSIS OF THE DECONGESTANT 48
FIGURE 4 GLOBAL DECONGESTANT MARKET, BY PRODUCT TYPE, 2024 (% SHARE) 53
FIGURE 5 GLOBAL DECONGESTANT MARKET, BY FORMULATION, 2024 (% SHARE) 56
FIGURE 6 GLOBAL DECONGESTANT MARKET, BY CATEGORY, 2024 (% SHARE) 58
FIGURE 7 GLOBAL DECONGESTANT MARKET, BY APPLICATION, 2024 (% SHARE) 61
FIGURE 8 GLOBAL DECONGESTANT MARKET, BY AGE GROUP, 2024 (% SHARE) 63
FIGURE 9 GLOBAL DECONGESTANT MARKET, BY DISTRIBUTION CHANNEL, 2024 (% SHARE) 65
FIGURE 10 GLOBAL DECONGESTANT MARKET MAJOR PLAYERS MARKET SHARE ANALYSIS, 2024 (%) 128
FIGURE 11 PFIZER. COMPANY: SWOT ANALYSIS 130
FIGURE 12 CIPLA LTD. SWOT ANALYSIS 132
FIGURE 13 GLAXOSMITHKLINE (GSK)/ PANADOL : SWOT ANALYSIS 134
FIGURE 14 JOHNSON & JOHNSON: SWOT ANALYSIS 136
FIGURE 15 APTARGROUP, INC. COMPANY: SWOT ANALYSIS 139
FIGURE 16 PROCTOR & GAMBLE COMPANY SWOT ANALYSIS 141
FIGURE 17 RECKITT BENCKISER GROUP PLC CHEMICAL LTD: SWOT ANALYSIS 143
FIGURE 18 SANOFI: SWOT ANALYSIS 146
FIGURE 19 PERRIGO COMPANY PLC: SWOT ANALYSIS 149
FIGURE 20 DR. REDDY’S LABORATORIES: SWOT ANALYSIS 151
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們